explore -WSS

explore

author：entertainment 2025-10-02 20:49:32 - browse：42122

Kevin Sayer, CEO of Dexcom Dexcom

For years, diabetes tech company Dexcom has been striving to get its continuous glucose monitors into the hands of type 2 diabetes patients. Last week at the American Diabetes Association’s conference, the company unveiled plans for software built entirely for these patients, including ones who don’t take insulin.

“We’ve been so focused on things that match the needs of somebody who manages diabetes every minute of every day, and insulin delivery,” Kevin Sayer, CEO of Dexcom, told STAT. “This new product is going to be designed to address the needs of somebody with diabetes who’s not doing that, who has type 2 diabetes and is on other drugs.”

Continuous glucose monitoring is already well-established among people with type 1 diabetes, who rely on constant insulin therapy. The technology, which helps patients noninvasively monitor their blood sugar levels and control their insulin pump in real time, has grown rapidly in use over the years, culminating in a $5 billion market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Vertex cell therapy lets patients with type 1 diabetes stop insulin

hotspot

WSS

Crowdfunding for unproven stem cell procedures spreads misinformation

Change Healthcare: What is it, why does its cyberattack matter?

Change Healthcare: What is it, why does its cyberattack matter?

Why Talkspace is targeting Medicare, a tricky market

A letter from the executive editor: The 2023 STATUS List

Readout Newsletter: BridgeBio, Akero, and human embryo models

leisure time

explore

explore

The high cost of giving birth even with insurance

Pregnant women don't need prenatal multivitamins, study concludes

Hepatitis C has a cure — but many Americans still lack access to it

Pregnant women don't need prenatal multivitamins, study concludes

Trump demands the U.S. pay no more for drugs than other countries … again

Prescription digital therapeutics are key to pharma’s future

DIEP, the 'gold standard' of breast reconstruction, is under threat

Beware reading your test results before your doctor does

Heart attack and stroke risk calculators need revising

The biotech scorecard for Q3: 15 stock

entertainment

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

State of the Union pitch: Bigger Medicare drug price negotiations

Biden's 'march

Security flaws in third

Drug cartel violence flares in western Mexico after vigilante leader's killing

Stem cell biologist probes earliest stages of human development

focus

focus

hotspot

leisure time